High Intensity Focused Ultrasound (HIFU) unit, Department of Urology, Churchill Hospital, Headington, Oxford, OX3 7LE
- Senior Clinical Scientist
- Honorary Consultant in HIFU Therapy
Professor Feng Wu received his medical training at Chongquing Medical University in China. In 1988 he began his research career in high intensity focused ultrasound (HIFU) therapy, and developed his own clinical HIFU device, with his work largely dedicated to treating solid tumors, including those of the liver, kidney, breast, pancreas, uterus, bone, and soft tissues. Until now Professor Wu and his teams have treated more than 50,000 patients, the largest population of HIFU treated cancer patients in the world.
In 2002, Professor Wu was invited to help establish the first clinical HIFU Unit in the United Kingdom, and to assist in running clinical HIFU trials for the treatment of tumour patients in Churchill Hospital, Oxford University Hospitals. His pivotal role in bringing this emerging technology to the UK has resulted in him becoming the first Chinese-trained clinician ever to be entered directly onto the specialist register in the UK - under the newly created Specialty of High Intensity Focused Ultrasound Therapy.
Professor Wu is currently working as HIFU Consultant at Oxford University Hospitals, and also serving as Senior Clinical Scientist at Nuffield Department of Surgical Sciences, University of Oxford. He has published more than 200 papers in peer-reviewed journals and seven book chapters related to HIFU therapy, and served as Editor-in-Chief in the World Journal of Surgical Procedure and Editorial Board Member in nine peer-reviewed journals. He was one of the founders for International Society for Therapeutic Ultrasound (ISTU), and was selected as Secretary-General of ISTU for six consecutive years (2001-2006). Professor Wu received the Society’s William and Francis Fry Award in 2013, and served as Honorary Symposium President for the 4th International Symposium on Current and Future Applications of Focused Ultrasound in 2014.
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.
Lyon PC. et al, (2018), Lancet Oncol, 19, 1027 - 1039
High-intensity focused ultrasound in the treatment of breast tumours.
Peek MCL. and Wu F., (2018), Ecancermedicalscience, 12
High-intensity focused ultrasonic ablation of sacral chordoma is feasible: a series of four cases and details of a national clinical trial.
Gillies MJ. et al, (2017), Br J Neurosurg, 31, 446 - 451
Cavitation enhances coagulated size during pulsed high-intensity focussed ultrasound ablation in an isolated liver perfusion system
Zhao LY. et al, (2017), International Journal of Hyperthermia, 33, 343 - 353
Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours.
Lyon PC. et al, (2017), J Ther Ultrasound, 5